Image Credit: Adobe Stock Images/Ishika.com

Noom, an online weight loss company, is unveiling its Microdose GLP-1^Rx Program, a service intended to limit side effects via personalized microdoses of GLP-1s, when clinically appropriate of course.¹

The initial price of the program is $119 to start, and $199 per month for a maximum 0.6-milligram dose thereafter. The prices include the meds (if prescribed), along with the company’s GLP-1 Companion that offers clinical care, a personalized healthy habits program, and coaching.

GLP-1 cost disparities highlight need for affordable alternatives

The obesity rate in the United States is starting to level off, but it continues to be highest among developed nations. In fact, more than 40% of Americans are classified as obese, compared to 26% in the UK, 23% in Germany, and just 10% in France. Meanwhile, GLP-1 drugs cost up to five times more in the US than in these countries.¹

Noom notes that there are three essential hurdles that are hindering progress along this front:

• The cost of medication
• The sides effects of medication
• An absence of sustainable behavior change

In fact, among patients who begin utilizing GLP-1s, over 50% of them stop as a result of cost, while 36% stop because of side effects.

Noom offers compounded semaglutide at a lower dose and price point

Affordability of GLP-1 meds are certainly an ongoing issue in the United States, when compared with other nations. For context, cash-pay patients in the US could pay $499 monthly, compared with $99 a month elsewhere. That was part of the reason why Noom decided to start selling small doses of compounded versions of Wegovy, the prescription medication developed by Novo Nordisk.²

Earlier this week, Reuters also confirmed³ that Noom would continue to sell the compounded semaglutide moving forward. It would be at aforementioned 0.6-milligram dose, as opposed to Novo’s version of 2.4 milligrams.

Noom executives feel that their Microdose GLP-1^Rx Program is more than capable of tackling those challenges.

“In the Microdose GLP-1^Rx Program, we set out to virtually eliminate side effects for the vast majority, so that more than 70% of people would encounter no side effects. In both my clinical experience and evidence in published studies, it is clear that many people discontinue GLP-1 treatment because of side effects,” commented Dr. Jeffrey Egler, Noom’s chief medical officer. “The Noom Microdose GLP-1^Rx Program was designed to address this issue by introducing GLP-1s gradually and sustaining them at a microdose level, as part of a larger holistic behavior change platform, which we call our GLP-1 Companion. This approach helps more patients stay on the treatment, experience the full health benefits of these medications, and make real progress in reducing obesity and overweight rates in the United States.”

Noom reports strong early outcomes with microdosing strategy

This gradual approach referenced by Egler is Noom’s “low and slow” titration approach with microdoses, which are considered fractions of the standard medication doses, 25% or less. Noom’s data has shown that members have lost up to 11 pounds in 30 days and up to 17 pounds in 60 days by taking these microdoses.

“The latest science demonstrates that we should be thinking about GLP-1 medication differently,” said Dr. Jeffrey Egler. “GLP-1s are no longer only useful for weight loss and diabetes—they are critical for building metabolic resilience and reducing inflammation, making them a powerful component of whole-person, lasting health. For our patients, we see GLP-1s as the first step in an extraordinary journey to true vitality.”

References

1. Noom Launches Microdose GLP-1 Program, Enabling Weight Loss Without the Side Effects and Priced at $119 to Start, Including Medication and Microhabits Program. GlobeNewswire. August 4, 2025. Accessed August 5, 2025. https://www.globenewswire.com/news-release/2025/08/04/3126585/0/en/Noom-Launches-Microdose-GLP-1-Program-Enabling-Weight-Loss-Without-the-Side-Effects-and-Priced-at-119-to-Start-Including-Medication-and-Microhabits-Program.html

2. Saraceno N. Noom to Sell Microdoses of Wegovy. Pharmaceutical Commerce. May 21, 2025. Accessed August 5, 2025. https://www.pharmaceuticalcommerce.com/view/noom-to-sell-microdoses-wegovy

3. Noom Launches Low Dose of Compounded Weight-Loss Drug For $119. Reuters. August 4, 2025. Accessed August 5, 2025. https://www.reuters.com/business/healthcare-pharmaceuticals/noom-launches-low-dose-compounded-weight-loss-drug-119-2025-08-04/